Few studies are available in human populations investigating involvement of vascular inflammation and oxidative stress-related dysfunctional transformation of high-density lipoprotein (HDL) in establishing cardiovascular disease (CVD) risk. To this end, the current work investigated a subgroup of post-infarction patients at high-risk for recurrent events defined by high levels of HDL cholesterol (HDL-C) and concurrently high levels of C-reactive protein (CRP). Thrombospondin-4 (TSP-4), a matricellular protein of vessel walls associated with inflammation, was investigated in terms of CVD risk using multivariable modelling with a well-characterised functional genetic polymorphism of THBS4 (A387P, rs1866389) along with previously demonstrated risk-related functional genetic polymorphisms of CYBA (C242T, rs4673) and CETP (TaqIB, rs708272), and a set of blood markers. Results revealed risk-association for the gain-of-function P-allele of the THBS4 polymorphism (hazard ratio 2.00, 95% confidence interval 1.10–3.65, p=0.024). Additionally, von Willebrand factor was associated with D-dimer levels in the higher-risk P allele patients suggestive of a connection between endothelial dysfunction and thrombogenesis. In conclusion, TSP-4, a matricellular protein involved in regulating vascular inflammation, plays a role in establishing recurrent coronary risk in postinfarction patients with high levels of HDL-C and CRP. Further studies should focus on additional effects of vascular inflammatory processes on anti-atherogenic functionality of HDL particles.
2
Shao B,
Oda M,
Oram JF.
et al. Myeloperoxidase: an oxidative pathway for generating dysfunctional high-density lipoprotein. Chem Res Toxicol 2010; 23: 447-454.
4
Kontush A,
Chapman MJ.
Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 2006; 58: 342-374.
7
Corsetti JP,
Gansevoort RT,
Navis GJ.
et al. LPL Polymorphism (D9N) Predicts Cardiovascular Disease Risk Directly and Through Interaction with CETP Polymorphism (TaqIB) in Women with High HDL Cholesterol and CRP. Atherosclerosis 2011; 214: 373-376.
8
Corsetti JP,
Ryan D,
Rainwater DL.
et al. CETP Polymorphism (TaqIB) Associates with Risk in Postinfarction Patients with High HDL Cholesterol and High CRP Levels. Arterioscler Thromb Vasc Biol 2010; 30: 1657-1664.
9
Corsetti JP,
Ryan D,
Moss AJ.
et al. NAD(P)H oxidase polymorphism (C242T) and high HDL-C associate with recurrent coronary events in post infarction patients. Atherosclerosis 2007; 196: 461-468.
10
Topol EJ,
McCarthy J,
Gabriel S.
et al. Single nucleotide polymorphisms in multiple novel thrombospondin genes may be associated with familial premature myocardial infarction. Circulation 2001; 104: 2641-2644.
13
Thompson A,
Di Angelantonio E,
Sarwar N.
et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary Risk. J Am Med Assoc 2008; 299: 2777-2788.
14
Dullaart RPF,
Sluiter W.
Common variation in the CETP gene and the implications for cardiovascular disease and its treatment: an updated analysis. Pharmacogenomics 2008; 9: 747-763.
15
Guzik TJ,
West NEJ,
Black E.
et al. Functional effect of the C242T polymorphism in the NAD(P)H oxidase p22phox gene on vascular superoxide production in atherosclerosis. Circulation 2000; 102: 1744-1747.
18
Corsetti JP,
Rainwater DL,
Moss AJ.
et al. High lipoprotein-associated phospholipase A2 is a risk factor for recurrent coronary events in postinfarction patients. Clin Chem 2006; 52: 1331-1338.
20
Goldenberg I,
Moss AJ,
Block R.
et al. Polymorphism in the cholesteryl ester transfer protein gene and the risk of early onset myocardial infarction among cigarette smokers. Ann Noninv Electrocardiol 2007; 12: 364-374.
23
Zareba W,
Pancio G,
Moss AJ.
et al. Increased level of von Willebrand factor is significantly and independently associated with diabetes in postinfarction patients. Thromb Haemost 2001; 86: 791-799.
24
Koch W,
Hoppmann P,
de Waha A.
et al. Polymorphisms in thrombospondin genes and myocardial infarction: a case-control study and a meta-analysis of available evidence. Hum Mol Gen 2008; 17: 1120-1126.
26
Stenina I O,
Byzova TV,
Adams JC.
et al. Coronary artery disease and the thrombospondin single nucleotide polymorphisms. Int J Biochem Cell Biol 2004; 36: 1013-1030.
27
Stenina OI,
Shailesh YD,
Krukovets I.
et al. Thrombospondin-4 and its variants expression and differential effects on endothelial cells. Circulation 2003; 108: 1514-1519.
